<DOC>
	<DOCNO>NCT02991599</DOCNO>
	<brief_summary>This randomize , control trial . The study evaluate immunogenicity , immune persistence , safety 20 µg 60 µg recombinant hepatitis B vaccine three injection month 0 , 1 , 6 methadone maintenance treatment patient .</brief_summary>
	<brief_title>Immunogenicity Hepatitis B Vaccination Methadone Maintenance Treatment Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Aged 18 70 year enrolment Serologically negative hepatitis B surface antigen ( HBsAg ) hepatitis B surface antibody ( antiHBs ) enrollment Willing adhere study protocol Being pregnant Intolerance allergy component vaccine Any vaccination month precede enrollment Ongoing opportunistic infection Liver disease Hematological disorder Cancer Unexplained fever week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis B , Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>methadone maintenance treatment</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>